OR WAIT null SECS
A new report highlights physical, social, and economic challenges of migraine.
It is important for healthcare executives to recognize the impact migraines have on people at home and in the workplace, as there is a serious need for additional treatment options, according to a new report.
The 2018 Migraine Impact Report evaluates the physical, social, and economic challenges of migraine. The Lilly-sponsored quantitative opinion survey included responses from 1,018 U.S. adults, including 518 people who have been diagnosed with migraine by a healthcare provider, 200 people who know someone with migraine, and 300 community members who do not know someone with migraine.
Among those surveyed, people diagnosed with migraine experienced on average 15.4 completely pain-free days over the previous 30 days. They also noted that the symptoms of their migraine prevented them from doing what they wanted to do for one week (6.9 days) over the previous 30 days.
“More than 36 million Americans battle migraine, many of whom lack a treatment option that addresses their symptoms and allows them to function in their day-to-day lives or is tolerable for them,” says Sheena Aurora, MD, medical fellow at Eli Lilly and Company.
Notably, the survey found:
Some additional findings from the survey include:
As a practicing neurologist, Aurora encourages others across the industry to prioritize and recognize the impact of migraine and the importance of new treatment options for this devastating disease.
“Despite its prevalence, migraine is often underestimated or dismissed as ‘simply a headache,’” Aurora says. “Migraine is a neurologic disease that can seriously affect a person’s life, and there are many people living with migraine who are unable to work and take care of their families. In fact, millions of people with migraine are losing at least one month per year to the disease-something I saw firsthand with many patients.”
Over the last two decades, innovation in the migraine treatment space has been limited-“but with new preventive therapies on the horizon, we believe that these new options may substantially improve care for those living with this disease,” says Aurora.
Next: Pipeline migraine drugs
Currently, the drug development pipeline is rich with products nearing market availability for both the prevention and treatment of migraine. The most prominent focus of this pipeline activity is a new and very promising category of drug products known as CGRP (calcitonin gene-related peptide) antagonists. Researchers have determined that CGRP levels are highly elevated in migraine sufferers, and medications that can bind to and inhibit the activity of CGRP may yield significant value in helping to better manage migraine and cluster headache.
There are currently four CGRP antagonists in late-stage development. Recent late-stage clinical trials with these drugs demonstrate significant reductions in monthly migraine or headache days compared to placebo, and with minimal side effects, according to a study published in Current Treatments in Neurology.
Other abortive treatment pipeline drugs include:
In December 2017, Lilly announced positive results from the second of two phase 3 studies evaluating lasmiditan for the acute treatment of migraine. Lilly plan to submit a New Drug Application (NDA) for lasmiditan to the FDA in the second half of 2018.
While all of these agents offer the neurology community and migraine sufferers renewed hope for additional treatment alternatives, such hope must be balanced with questions that will remain largely unanswered at product introduction: